Stephen Eck, M.D., Ph.D., Astellas Pharma Global Development

Stephen Eck, M.D., Ph.D, is Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma Global Development (Headquartered in Northbrook, IL). He is directly responsible for the oversight of oncology drug development plans. Much of this work is focused on special cancer populations for which unique biology enables the development of personalized cancer therapies. Dr. Eck previously served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company (2007-2011) where he was responsible for the clinical pharmacology components of drug development, including both early phase clinical studies and late-stage drug development studies. His group also developed the biomarkers and companion diagnostics needed for effective decision-making and for tailoring therapeutics to the right patient population. An essential part of this work was conducted in the Diagnostic and Experimental Medicine Group and the Laboratory for Experimental Medicine. Prior to Joining Lilly, Dr. Eck served in a variety of drug development leadership roles at Pfizer, Inc (2002-2007).

Dr. Eck is a board certified Hematologist/Oncologist with broad drug development experience in Oncology and Neuroscience. He is a Fellow of the American Association for the Advancement of Science. He serves on the Scientific Advisory Board of the ACGT Foundation, which supports academic cancer research, and is a member of the Scientific Advisory Committee of the Fairbanks Institute, an institution dedicated to developing data banks to enable personalized medicine. He also serves on the Advisory Board of the Keck Graduate School (Claremont, CA), and is a Board member of the Personalized Medicine Coalition.

Read Stephen Eck’s latest contributions to The Age of Personalized Medicine Blog.

%d bloggers like this: